BR112019021853A2 - Compostos de inibidor de vmat2 e composições dos mesmos - Google Patents
Compostos de inibidor de vmat2 e composições dos mesmos Download PDFInfo
- Publication number
- BR112019021853A2 BR112019021853A2 BR112019021853-0A BR112019021853A BR112019021853A2 BR 112019021853 A2 BR112019021853 A2 BR 112019021853A2 BR 112019021853 A BR112019021853 A BR 112019021853A BR 112019021853 A2 BR112019021853 A2 BR 112019021853A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- same
- inhibitor compounds
- vmat2 inhibitor
- Prior art date
Links
- UDELQOQFKFGXKY-UYAOXDASSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CC3)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CC3)N2C1 UDELQOQFKFGXKY-UYAOXDASSA-N 0.000 description 1
- SSVDACKPVANQIL-TZIWHRDSSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CCC3)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CCC3)N2C1 SSVDACKPVANQIL-TZIWHRDSSA-N 0.000 description 1
- AENINHKHDUSDOM-IEBWSBKVSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCC(F)(F)F)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCC(F)(F)F)N2C1 AENINHKHDUSDOM-IEBWSBKVSA-N 0.000 description 1
- LCICDLKGBXBEGT-UYAOXDASSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCC(F)(F)F)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCC(F)(F)F)N2C1 LCICDLKGBXBEGT-UYAOXDASSA-N 0.000 description 1
- IXIYNLWTQXWQQC-SJLPKXTDSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCF)N2C1 IXIYNLWTQXWQQC-SJLPKXTDSA-N 0.000 description 1
- IUXQTSFZTSAVFK-IEBWSBKVSA-N CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCOC)N3C1 Chemical compound CC(C)(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCOC)N3C1 IUXQTSFZTSAVFK-IEBWSBKVSA-N 0.000 description 1
- XSJZLZFCSPLOGV-IEBWSBKVSA-N CC(C)Oc(cc(CCN1[C@@H]2CN(C)[C@H](CC(C)(C)C)C1)c2c1)c1OC Chemical compound CC(C)Oc(cc(CCN1[C@@H]2CN(C)[C@H](CC(C)(C)C)C1)c2c1)c1OC XSJZLZFCSPLOGV-IEBWSBKVSA-N 0.000 description 1
- YNXYNRFUMLCJMA-SJLPKXTDSA-N CCOc(cc(CCN1[C@@H]2CN(C)[C@H](CC(C)(C)C)C1)c2c1)c1OC Chemical compound CCOc(cc(CCN1[C@@H]2CN(C)[C@H](CC(C)(C)C)C1)c2c1)c1OC YNXYNRFUMLCJMA-SJLPKXTDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
é fornecido um composto selecionado de compostos de fórmula (i) e hidratos, solvatos e sais farmaceuticamente aceitáveis do mesmo: (i) em que r1, r2, r3 e r4 são como definidos aqui. tais compostos são inibidores do transportados da monoamina vesicular 2 (vmat2) e têm utilidade para o tratamento, por exemplo, doenças e distúrbios neurológicos e psiquiátricos. são também descritas composições contendo tais compostos em combinação com um veículo farmaceuticamente aceitável, bem como os métodos relacionados ao seu uso em indivíduos em necessidade dos mesmos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762487413P | 2017-04-19 | 2017-04-19 | |
US62/487,413 | 2017-04-19 | ||
US201862652837P | 2018-04-04 | 2018-04-04 | |
US62/652,837 | 2018-04-04 | ||
PCT/US2018/028031 WO2018195121A1 (en) | 2017-04-19 | 2018-04-17 | Vmat2 inhibitor compounds and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019021853A2 true BR112019021853A2 (pt) | 2020-05-26 |
Family
ID=62111264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019021853-0A BR112019021853A2 (pt) | 2017-04-19 | 2018-04-17 | Compostos de inibidor de vmat2 e composições dos mesmos |
Country Status (17)
Country | Link |
---|---|
US (1) | US11040970B2 (pt) |
EP (1) | EP3612532B1 (pt) |
JP (1) | JP7170662B2 (pt) |
KR (1) | KR20190140968A (pt) |
CN (1) | CN110770236B (pt) |
AU (1) | AU2018254429A1 (pt) |
BR (1) | BR112019021853A2 (pt) |
CA (1) | CA3060251A1 (pt) |
CL (1) | CL2019002919A1 (pt) |
CO (1) | CO2019011604A2 (pt) |
ES (1) | ES2971230T3 (pt) |
JO (1) | JOP20190239A1 (pt) |
MA (1) | MA50145A (pt) |
MX (1) | MX2019012336A (pt) |
PE (1) | PE20191784A1 (pt) |
TW (1) | TW201841913A (pt) |
WO (1) | WO2018195121A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110740731A (zh) | 2017-01-27 | 2020-01-31 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
JP7250006B2 (ja) | 2017-09-21 | 2023-03-31 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット |
JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 特定のvmat2インヒビターを投与するための方法 |
JP2021528386A (ja) * | 2018-06-14 | 2021-10-21 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Vmat2インヒビター化合物、上記化合物に関する組成物および方法 |
SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
WO2020086765A1 (en) * | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of pd-1/pd-l1 inhibitor |
BR112023016273A2 (pt) | 2021-03-22 | 2023-10-03 | Neurocrine Biosciences Inc | Inibidores de vmat2 e métodos de uso |
WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
CA2528784C (en) | 2003-06-20 | 2012-02-21 | Markus Boehringer | Hexahydropyridoisoquinolines as dpp-iv inhibitors |
JP2008509925A (ja) | 2004-08-13 | 2008-04-03 | オメロス コーポレイション | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
CN101553487B (zh) | 2006-11-08 | 2012-06-13 | 纽罗克里生物科学有限公司 | 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 |
FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2009126305A1 (en) | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University | Glucose metabolism modulating compounds |
NO3061760T3 (pt) | 2008-09-18 | 2018-04-07 | ||
WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
CN102285984B (zh) | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
WO2014043866A1 (zh) | 2012-09-19 | 2014-03-27 | 中国科学院福建物质结构研究所 | 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途 |
MX2016010071A (es) | 2014-02-07 | 2017-04-27 | Neurocrine Biosciences Inc | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. |
KR102586138B1 (ko) | 2015-02-06 | 2023-10-05 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법 |
UA126394C2 (uk) | 2016-12-22 | 2022-09-28 | Інсайт Корпорейшн | Похідні бензоксазолу як імуномодулятори |
TWI798192B (zh) | 2016-12-22 | 2023-04-11 | 美商英塞特公司 | 免疫調節劑化合物及使用方法 |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko unknown
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en active Application Filing
- 2018-04-17 ES ES18722357T patent/ES2971230T3/es active Active
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2019002919A1 (es) | 2020-01-17 |
CO2019011604A2 (es) | 2019-10-31 |
ES2971230T3 (es) | 2024-06-04 |
TW201841913A (zh) | 2018-12-01 |
CA3060251A1 (en) | 2018-10-25 |
JP2020517607A (ja) | 2020-06-18 |
JOP20190239A1 (ar) | 2019-10-09 |
PE20191784A1 (es) | 2019-12-24 |
MA50145A (fr) | 2020-07-29 |
EP3612532A1 (en) | 2020-02-26 |
US20200131173A1 (en) | 2020-04-30 |
US11040970B2 (en) | 2021-06-22 |
MX2019012336A (es) | 2020-07-14 |
AU2018254429A1 (en) | 2019-11-07 |
CN110770236A (zh) | 2020-02-07 |
JP7170662B2 (ja) | 2022-11-14 |
EP3612532C0 (en) | 2023-12-13 |
KR20190140968A (ko) | 2019-12-20 |
WO2018195121A1 (en) | 2018-10-25 |
CN110770236B (zh) | 2023-03-24 |
EP3612532B1 (en) | 2023-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019021853A2 (pt) | Compostos de inibidor de vmat2 e composições dos mesmos | |
BR112019002610A2 (pt) | piridopirimidinonas inibidoras de cdk2/4/6 | |
UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
ECSP109958A (es) | Derivados de pirimidina 934 | |
MX2019006843A (es) | Inhibidor de cdk4/6. | |
EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
NI200900181A (es) | Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos. | |
RS52613B (en) | CARBAMOIL-CYCLOHEXANES FOR THE TREATMENT OF ACUTE MANIA | |
UY37764A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
BR112022005736A2 (pt) | Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas | |
BR112018000925A2 (pt) | composto heterocíclico contendo nitrogênio | |
MX2020013811A (es) | Compuestos. | |
PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
BR112022005723A2 (pt) | Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas | |
CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B10A | Cessation: cessation confirmed | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |